Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting

Abstract

The present work critically examines the long-term results, survival outcome and toxicity profile of the indigenous ¹⁷⁷Lu-DOTATATE (produced through direct neutron activation of enriched ¹⁷⁶Lu) in metastatic progressive NETs across a wide range of primary sites and malignancies. Such long-term outcome data establishes the favourable impact of PRRT in a wide patient base and also the therapeutic efficacy of the product.